Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Announcement: Sales Force Effectiveness Japan 2013 to Be Held on July 16, 17
June 11, 2013
- Ethical, OTC Drug Sales Up 1.3% and 9.5%: Crecon Report
June 10, 2013
- Bayer to File Eylea for mCNV in Japan Later This Year
June 10, 2013
- Taiho’s TS-1 Non-Inferior to UFT/LV in Resected Colon Cancer Patients: PIII Study
June 7, 2013
- Nichi-Iko Announces Launching of Authorized Generic of Allegra in June; Is Late Launch Part of Sanofi’s Carefully Worked-out Strategy?
June 7, 2013
- Use of Contract MRs on the Rise among Smaller Drug Makers; JCSOA’s Goal of “5,000 CMRs by 2015” May Be Realistic
June 7, 2013
- Zeria, Astellas Launch World’s First FD Treatment
June 6, 2013
- DSP Completes Construction of New Chemical Research Facility in Osaka
June 6, 2013
- AZ Decides Not to Proceed with Regulatory Filings for Novel Oral RA Treatment Fostamatinib
June 6, 2013
- Nihon Chouzai to Increase Its Subsidiary’s Generic Production Capacity
June 5, 2013
- Takeda Unveils Interim Data from ADCETRIS PI Study in Pediatric Patients
June 5, 2013
- Fujifilm, Dr. Reddy’s Terminate Plan for Joint Venture for Generics
June 5, 2013
- Novartis Pharma to Cut Pay of 9 Top Officials and Suspend Promotion of Ethical Drugs for 5 Days Over Diovan Scandal
June 5, 2013
- Nippon Chemiphar to Outsource Production to Vietnam Next Spring
June 5, 2013
- BMKK, Ono Start Copromotion of Orencia following Lifting of All-Case Surveillance
June 5, 2013
- Four Drug Makers File Their Anticancer Drugs for FOLFIRINOX Therapy for Pancreatic Cancer
June 4, 2013
- Japan Pharma Leaders: Drug Development via GHIT Fund Hoped to Fuel Economic Growth in Developing World
June 4, 2013
- Fujifilm Initiates PI Study of MDS Treatment FF-10501 in Japan
June 4, 2013
- AZ to Assess Possibility of EGFR Mutation Testing via Blood in Japan-Europe Study
June 3, 2013
- Four Pharmas Launch Filgrastim, Third Biosimilars in Japan
June 3, 2013
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…